Anti-Human sRANKL
Anti-Human sRANKL
Product No.: R139
- -
- -
Target sRANKL Product Type Polyclonal Antibody Alternate Names CD254, TRANCE, hRANKL2, sOdf, TNF-Related Activation-Induced Cytokine [TRANCE], Osteoprotegrin Ligand [OPGL], Osteoclast Differentiation Factor [ODF], TNFSF11 Applications ELISA Cap , ELISA Indirect , N , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Rabbit Immunogen Purified Recombinant sRANKL (>98%) Formulation This antigen affinity purified polyclonal antibody is aseptically filtered and lyophilized from PBS with no carrier proteins or preservatives added. Storage and Handling The lyophilized antibody should be stored desiccated at -20°C. The reconstituted antibody can be stored for at least six weeks at 4°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day Ambient RRIDAB_2831727 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Rabbit Anti-Human Soluble Receptor Activator of NF-KappaB Ligand (sRANKL) recognizes Human sRANKL. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research. Background RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.1 RANKL is essential for osteoclast formation, activation, and survival.2 RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.3 RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.4 Antigen DetailsPubMed NCBI Gene Bank ID UniProt.org References & Citations1. H Takayanagi et al. (2003) Arthritis Res Ther. 5: 20
2. Kostenuik PJ et al. (2005) Endocrinology 146: 3235
3. Holven KB et al. (2009) Stroke 40: 241
4. Penninger JM et al. (2008) Ann N Y Acad Sci. 1143: 123
Technical Protocols |
Related Products
- -
- -
Prod No. | Description |
---|---|
R1243 | |
R139 | |
R1145 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.